HealthInsights

The autoimmune illness known as primary biliary cholangitis (PBC) , formerly known as primary biliary cirrhosis, develops in the periportal inflammatory cholestasis that is brought on by the progressive degeneration of intrahepatic bile ducts. Hepatic cholestasis with persisting cirrhosis and portal hypertension. UDCA and OCALIVA – The Only Available Therapies for Primary Biliary Cholangitis Treatment Despite Controversies  . The only two primary biliary cholangitis medications that the Food and Drug Administration (FDA) has approved for treating primary biliary cholangitis are ursodeoxycholic acid (UDCA) and obeticholic acid (OCALIVA). Despite the development of promising second-line treatments for PBC patients who are UDCA-intolerant or UDCA-naive, UDCA is still the preferred first-line treatment for primary biliary cholangitis . The fundamental causes of the continued trust are the UDCA's good long-term effectiveness and safety profile and its reasonably priced primary biliary ...

Oral diseases , which impact around 3.5 billion people worldwide, are one of the major global health burdens while being completely preventable. Gum (periodontal) disease and dental caries, sometimes referred to as cavities or tooth decay, are the two conditions that have the biggest negative effects on oral health and account for the majority of the burden of oral illness. Significant risk factors for the emergence of oral disorders include consuming sugar-rich foods and snacks, smoking, drinking alcohol, and ingesting some hazardous foods and beverages. Expanding urbanization, filthy conditions, changing lifestyles, and restricted access to oral health care services all have an impact on oral health disorders. The WHO estimates that 520 million children and over 2 billion people worldwide suffer from primary tooth decay in 2019. More than 40% of individuals reported having oral pain in 2018 as well, and by the age of 34, more than 80% of people will have had at least one cavity. Unt...